In July 2022, WHO issued guidelines recommending the use of injectable cabotegravir as PrEP (CAB PrEP) for HIV and PEPFAR’s 2023 COP guidance encourages countries to begin planning for its rollout. While CAB PrEP is not yet approved for use in Asia, applications for regulatory approval have been submitted in China, Malaysia, Myanmar, Philippines, Thailand, and Vietnam. To expedite CAB PrEP's availability and optimize impact, community preferences and potential access barriers must be well understood and addressed collaboratively by all stakeholders. This session will review evidence from recent CAB PrEP studies in Asia; share how community and government leaders are preparing for CAB PrEP introduction; provide an update on licensing and the outlook for access to CAB PrEP in Asia; and share practical tools and technical resources to help countries prepare for CAB rollout.